JP2016538545A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016538545A5 JP2016538545A5 JP2016530873A JP2016530873A JP2016538545A5 JP 2016538545 A5 JP2016538545 A5 JP 2016538545A5 JP 2016530873 A JP2016530873 A JP 2016530873A JP 2016530873 A JP2016530873 A JP 2016530873A JP 2016538545 A5 JP2016538545 A5 JP 2016538545A5
- Authority
- JP
- Japan
- Prior art keywords
- liver
- protein
- marker protein
- cell
- marker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004169 proteins and genes Human genes 0.000 claims 37
- 108090000623 proteins and genes Proteins 0.000 claims 37
- 239000003550 marker Substances 0.000 claims 31
- 238000000034 method Methods 0.000 claims 22
- 210000004027 cell Anatomy 0.000 claims 17
- 102000004243 Tubulin Human genes 0.000 claims 16
- 108090000704 Tubulin Proteins 0.000 claims 16
- 208000014018 liver neoplasm Diseases 0.000 claims 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims 16
- 206010019695 Hepatic neoplasm Diseases 0.000 claims 14
- 210000005229 liver cell Anatomy 0.000 claims 11
- 239000000090 biomarker Substances 0.000 claims 10
- 210000005228 liver tissue Anatomy 0.000 claims 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims 8
- 210000004881 tumor cell Anatomy 0.000 claims 8
- 108010019099 Aldo-Keto Reductase Family 1 member B10 Proteins 0.000 claims 6
- 102100026451 Aldo-keto reductase family 1 member B10 Human genes 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 6
- 230000027455 binding Effects 0.000 claims 4
- 238000012544 monitoring process Methods 0.000 claims 4
- 102100024682 14-3-3 protein eta Human genes 0.000 claims 3
- 101710188276 14-3-3 protein eta Proteins 0.000 claims 3
- 102000015827 Asporin Human genes 0.000 claims 3
- 108050004044 Asporin Proteins 0.000 claims 3
- 102000047200 Collagen Type XVIII Human genes 0.000 claims 3
- 108010001463 Collagen Type XVIII Proteins 0.000 claims 3
- 102000016359 Fibronectins Human genes 0.000 claims 3
- 108010067306 Fibronectins Proteins 0.000 claims 3
- 102100035220 Plastin-3 Human genes 0.000 claims 3
- 101710081133 Plastin-3 Proteins 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 3
- 238000003745 diagnosis Methods 0.000 claims 3
- 238000011269 treatment regimen Methods 0.000 claims 3
- 102000012123 Dihydropyrimidinase-related protein 3 Human genes 0.000 claims 2
- 108050002650 Dihydropyrimidinase-related protein 3 Proteins 0.000 claims 2
- 210000000013 bile duct Anatomy 0.000 claims 2
- 239000000872 buffer Substances 0.000 claims 2
- 230000029087 digestion Effects 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 210000002919 epithelial cell Anatomy 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 210000002381 plasma Anatomy 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 230000009870 specific binding Effects 0.000 claims 2
- 102100036238 Dihydropyrimidinase Human genes 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 208000007666 Klatskin Tumor Diseases 0.000 claims 1
- 101001018085 Lysobacter enzymogenes Lysyl endopeptidase Proteins 0.000 claims 1
- 102000004142 Trypsin Human genes 0.000 claims 1
- 108090000631 Trypsin Proteins 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 238000001574 biopsy Methods 0.000 claims 1
- 230000010109 chemoembolization Effects 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 108091022884 dihydropyrimidinase Proteins 0.000 claims 1
- 210000002767 hepatic artery Anatomy 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 210000003494 hepatocyte Anatomy 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 238000004949 mass spectrometry Methods 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 238000004393 prognosis Methods 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 210000003296 saliva Anatomy 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 238000012360 testing method Methods 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 230000007704 transition Effects 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- 239000012588 trypsin Substances 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1320061.3 | 2013-11-13 | ||
| GBGB1320061.3A GB201320061D0 (en) | 2013-11-13 | 2013-11-13 | Materials nad methods for diagnosis and prognosis of liver cancer |
| PCT/GB2014/053368 WO2015071669A2 (en) | 2013-11-13 | 2014-11-13 | Materials and methods for diagnosis and prognosis of liver cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016538545A JP2016538545A (ja) | 2016-12-08 |
| JP2016538545A5 true JP2016538545A5 (enExample) | 2018-04-12 |
Family
ID=49818578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016530873A Pending JP2016538545A (ja) | 2013-11-13 | 2014-11-13 | 肝臓癌の診断及び予後判定のための材料及び方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20160320395A1 (enExample) |
| EP (1) | EP3069142A2 (enExample) |
| JP (1) | JP2016538545A (enExample) |
| CA (1) | CA2928510A1 (enExample) |
| GB (1) | GB201320061D0 (enExample) |
| WO (1) | WO2015071669A2 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105288659B (zh) * | 2015-06-01 | 2019-07-26 | 北京泱深生物信息技术有限公司 | Tenm1基因及其表达产物在诊治乳头状腺癌的应用 |
| KR101750411B1 (ko) | 2015-07-10 | 2017-06-27 | 한국생명공학연구원 | 엑소좀 단백질 eif3a 특이반응 오토항체검출용 항원 조성물 및 이를 이용한 간암진단법 |
| FR3048780B1 (fr) * | 2016-03-11 | 2020-11-06 | Commissariat Energie Atomique | Procede de diagnostic in vitro d'atteintes hepatiques |
| EP3403100B1 (fr) * | 2016-01-15 | 2020-03-11 | Commissariat à l'Énergie Atomique et aux Énergies Alternatives | Procédé de diagnostic in vitro d'atteintes hépatiques |
| GB201616912D0 (en) * | 2016-10-05 | 2016-11-16 | University Of East Anglia | Classification of cancer |
| GB201619954D0 (en) * | 2016-11-25 | 2017-01-11 | Oncimmune Ltd | Antibody assay |
| WO2018136702A1 (en) | 2017-01-23 | 2018-07-26 | Regeneron Pharmaceuticals, Inc. | Hydroxysteroid 17-beta dehydrogenase 13 (hsd17b13) variants and uses thereof |
| CN115266962B (zh) * | 2017-03-31 | 2024-05-31 | 北京谷海天目生物医学科技有限公司 | 蛋白标志物在制备弥漫型胃癌分子分型的产品中的应用及弥漫型胃癌分子分型的分类器 |
| CA3059348A1 (en) | 2017-04-11 | 2018-10-18 | Regeneron Pharmaceuticals, Inc. | Assays for screening activity of modulators of members of the hydroxysteroid (17-beta) dehydrogenase (hsd17b) family |
| WO2018189215A1 (en) * | 2017-04-12 | 2018-10-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for predicting the survival time of a patient suffering from hepatocellular carcinoma |
| CN111183234A (zh) | 2017-10-11 | 2020-05-19 | 雷杰纳荣制药公司 | 在表达pnpla3 i148m变异的患者的肝病治疗中对hsd17b13的抑制 |
| CN109596829A (zh) * | 2017-12-07 | 2019-04-09 | 南京医科大学 | 一种肝癌标志蛋白及其检测方法 |
| WO2019115679A1 (en) * | 2017-12-13 | 2019-06-20 | Fundació Institut D'investigació En Ciències De La Salut Germans Trias I Pujol | A signature to assess prognosis and therapeutic regimen in liver cancer |
| KR20250154534A (ko) | 2018-03-21 | 2025-10-28 | 리제너론 파마슈티칼스 인코포레이티드 | 17β-하이드록시스테로이드 데하이드로게나제 유형 13 (HSD17B13) iRNA 조성물 및 그것의 사용 방법 |
| WO2020243329A1 (en) * | 2019-05-28 | 2020-12-03 | The Regents Of The University Of California | Methods for treating small cell neuroendocrine and related cancers |
| CA3166923A1 (en) * | 2020-02-10 | 2021-08-19 | Somalogic Operating Co., Inc. | Nonalcoholic steatohepatitis (nash) biomarkers and uses thereof |
| US20230313299A1 (en) * | 2020-03-02 | 2023-10-05 | Université De Strasbourg | Method for diagnosis and/or prognosis of liver disease progression and risk of hepatocellular carcinoma and discovery of therapeutic compounds and targets to treat liver disease and cancer |
| JP7471898B2 (ja) * | 2020-04-17 | 2024-04-22 | 合同会社Ｈ．Ｕ．グループ中央研究所 | 胆管がんのバイオマーカー |
| CN111748623B (zh) * | 2020-06-08 | 2022-11-04 | 郑州大学第一附属医院 | 肝癌患者是否复发的预测标志物及试剂盒 |
| CN111748624B (zh) * | 2020-06-08 | 2022-11-04 | 郑州大学第一附属医院 | 用于预测肝癌是否复发的生物标志物 |
| CN112961916B (zh) * | 2020-11-10 | 2024-03-12 | 上海市肿瘤研究所 | Akr1c3作为肝癌预后的生物学标志物及其应用 |
| CN112908470B (zh) * | 2021-02-08 | 2023-10-03 | 深圳市人民医院 | 一种基于rna结合蛋白基因的肝细胞癌预后评分系统及其应用 |
| CN113462777A (zh) * | 2021-06-28 | 2021-10-01 | 武汉大学 | P4hb在制备肝细胞癌早期诊断试剂盒及制备或筛选抗肝癌药物中的应用 |
| CN114814001B (zh) * | 2022-03-31 | 2023-02-21 | 武汉大学 | 用于制备肝癌检测试剂的新型代谢标志物及其应用 |
| CN115754290A (zh) * | 2022-09-26 | 2023-03-07 | 浙江大学 | 一种用于检测早期肝癌的试剂盒 |
| CN115807089B (zh) * | 2022-11-14 | 2024-09-13 | 石河子大学 | 肝细胞肝癌预后生物标志物及应用 |
| CN116338189B (zh) * | 2023-01-16 | 2025-08-22 | 浙江大学医学院附属第一医院 | 具有蛋白激酶功能的肿瘤标志物ckb在制备肿瘤诊断产品中的应用 |
| CN116386715A (zh) * | 2023-03-09 | 2023-07-04 | 福建医科大学孟超肝胆医院 | 用于原发性肝细胞癌蛋白质组分子分型诊断的特征蛋白及其应用 |
| CN117607438A (zh) * | 2023-11-23 | 2024-02-27 | 浙江大学 | 一种肝细胞癌鉴别诊断和分化程度检测方法 |
| CN119314683B (zh) * | 2024-12-17 | 2025-02-25 | 吉林大学第一医院 | 一种用于肝移植术后预测系统 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| EP0533838B1 (en) | 1990-06-11 | 1997-12-03 | NeXstar Pharmaceuticals, Inc. | Nucleic acid ligands |
| US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| DE60239962D1 (de) | 2001-08-14 | 2011-06-16 | Harvard College | Absolute quantifizierung von proteinen und modifizierten formen davon mittels mehrstufiger massenspektrometrie |
| US20060154312A1 (en) * | 2004-12-09 | 2006-07-13 | Sergei Agoulnik | Tubulin isotype screening in cancer therapy using halichondrin B analogs |
| JP2008522624A (ja) * | 2004-12-09 | 2008-07-03 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ヘミアスタリン（ｈｅｍｉａｓｔｅｒｌｉｎ）アナログを使用する癌治療におけるチューブリンのアイソタイプのスクリーニング |
| US20080161203A1 (en) * | 2006-12-27 | 2008-07-03 | Su Chun-Lin | Markers identified for liver fibrosis and cirrhosis and the microarray panel thereof |
| GB0704764D0 (en) | 2007-03-12 | 2007-04-18 | Electrophoretics Ltd | Isobarically labelled reagents and methods of their use |
| WO2009113495A1 (ja) * | 2008-03-12 | 2009-09-17 | 財団法人ヒューマンサイエンス振興財団 | 肝癌特異的発現遺伝子による肝癌の検査方法並びに肝癌の治療及び予防剤 |
| WO2011078311A1 (ja) * | 2009-12-25 | 2011-06-30 | 大鵬薬品工業株式会社 | 肝細胞癌治療のための抗腫瘍剤又は術後補助化学療法剤 |
| CA2844793A1 (en) * | 2011-08-31 | 2013-03-07 | Oncocyte Corporation | Methods and compositions for the treatment and diagnosis of cancer |
-
2013
- 2013-11-13 GB GBGB1320061.3A patent/GB201320061D0/en not_active Ceased
-
2014
- 2014-11-13 US US15/036,773 patent/US20160320395A1/en not_active Abandoned
- 2014-11-13 EP EP14814986.7A patent/EP3069142A2/en not_active Withdrawn
- 2014-11-13 CA CA2928510A patent/CA2928510A1/en not_active Abandoned
- 2014-11-13 WO PCT/GB2014/053368 patent/WO2015071669A2/en not_active Ceased
- 2014-11-13 JP JP2016530873A patent/JP2016538545A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016538545A5 (enExample) | ||
| Baek et al. | Development of a reverse transcription-loop-mediated isothermal amplification as a rapid early-detection method for novel SARS-CoV-2 | |
| Nallagangula et al. | Liver fibrosis: a compilation on the biomarkers status and their significance during disease progression | |
| Charville et al. | EWSR1 fusion proteins mediate PAX7 expression in Ewing sarcoma | |
| Chen et al. | Single-cell RNA-sequencing of migratory breast cancer cells: discovering genes associated with cancer metastasis | |
| Modlin et al. | Neuroendocrine tumor biomarkers: current status and perspectives | |
| Pillet et al. | Comparative evaluation of six commercialized multiplex PCR kits for the diagnosis of respiratory infections | |
| Du Preez et al. | The application of metabolomics toward pulmonary tuberculosis research | |
| Mok et al. | Association of kidney disease measures with cause-specific mortality: the Korean Heart Study | |
| Khan et al. | Role of TGF-β and BMP7 in the pathogenesis of oral submucous fibrosis | |
| Cabiati et al. | Osteopontin in hepatocellular carcinoma: A possible biomarker for diagnosis and follow-up | |
| BR112012032537A2 (pt) | biomarcadores de câncer de pulmão e suas utilizações | |
| JP2016507723A5 (enExample) | ||
| GB2478441A (en) | Lung cancer biomarkers and uses thereof | |
| BR112013003391B8 (pt) | Método para diagnosticar câncer pancreático em um indivíduo | |
| JP2014523521A5 (enExample) | ||
| BR112012019542A2 (pt) | "método para avaliar o estado renal em um indivíduo, medição de um ou mais biomarcadores, e, kit" | |
| Tan et al. | <? covid19?> The Virological, Immunological, and Imaging Approaches for COVID-19 Diagnosis and Research | |
| Liu et al. | The diagnostic role of miR-122 in drug-induced liver injury: a systematic review and meta-analysis | |
| Wu et al. | DNA-methylation signature accurately differentiates pancreatic cancer from chronic pancreatitis in tissue and plasma | |
| UA124522C2 (uk) | Спосіб кількісної оцінки рівнів простатичного антигену | |
| Mansilla et al. | The identification and isolation of CTCs: A biological Rubik’s cube | |
| Qin et al. | Combination of serum tumor markers dickkopf-1, DCP and AFP for the diagnosis of primary hepatocellular carcinoma | |
| CN105316404B (zh) | 系统性红斑狼疮生物标志物及其诊断试剂盒 | |
| JP2016519767A5 (enExample) |